SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- November 01, 2006 -- Novacea, Inc. (NASDAQ: NOVC) today announced that it has initiated a multicenter, Phase1b/2a open-label clinical trial of AQ4N (banoxantrone), in combination with radiotherapy and temozolomide, for safety, tolerability and activity in patients with newly diagnosed glioblastoma multiforme (GBM).
